Authors
Latest:
The Future of JAK InhibitorsPharma companies have faced hurdles in gaining approval of Janus kinase (JAK) inhibitors for the treatment of rheumatoid arthritis. Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey look at what can be learned from the lessons of the past.
Latest:
Advocacy and Access in a Complex MarketplaceNick Hicks and Bruno Santoni explore the complex plasma-derived medical products marketplace.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
Patent Protection for Cannabis?Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.
Latest:
In Blockchain We TrustThe next generation of supply chain shows an increasing need for blockchain technology.
Latest:
Is the Price Right? An Overview of US Pricing StrategiesBruno Delagneau reviews the current landscape for price-setting in the US and suggests that it’s time for pharma to change their practices.
Latest:
Bribery and Corruption Compliance in UK Pharma: Where Are We Now?When it first came into force the UK Bribery Act 2010 was deemed to be revolutionary. Looking back, what has been its impact on pharma? Chris Cartmell and Jo Pisano report.
Latest:
FDA's $100 Million RWE Project: Making It All It Can BeFDA's proposal to build a modern system to gather real-world evidence (RWE) from about 10 million individuals could have profound implications, but it will realize its potential only if FDA takes a more expansive view of what RWE can be, writes Paul Glimcher.
Latest:
RMAT Designations: Lessons Learned on the “Clinical Evidence” RequirementThe Regenerative Medicine Advanced Therapies (RMAT) designation was introduced by the 21st Century Cures Act as a pathway to accelerate FDA approval and market entry of regenerative medical therapies. Two years on, William Rose and Suchira Ghosh identify the trends in how FDA assesses the clinical evidence supporting successful RMAT candidates.
Latest:
Pharmacovigilance Software's “Salesforce” MomentAlthough it is unlikely that mock demonstrators will be seen at any drug information or regulatory conferences, pharmacovigilance software is indeed having its “Salesforce” moment.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Trust—Biotech’s Hidden AdvantageHow companies can trust now to cultivate corporate reputations that build business.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Diabetes Researchers Make Novel Connections with Graph TechnologyEmil Eifrem examines how life science researchers at Munich’s German Center for Diabetes Research are uncovering insights in their data with a new way of working with complex data
Latest:
Machine Learning: The Next Frontier in Commercial PlanningKeshia Vaughn looks at how machine learning can transform commercial planning and outlines what teams will need to deploy it effectively.
Latest:
Ascending the Uncanny Valley in HealthcareBeing more human in brand engagement doesn’t mean being less transparent
Latest:
Securing Medical Devices Means Securing NetworksOrganizations should focus just as much of their attention on securing the actual medical devices they produce as the network they depend on, writes Chris Souza.
Latest:
Reacting to Reference PricingThe industry should take a twin-track approach to the potential threat of the Trump administration's proposed move to reference pricing, writes Todd Edgar.
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
5 Ways to Shape a Regulatory Affairs Workforce for the FuturePharmaceutical regulatory divisions should use the same discipline, rigor and focus on the talent pipeline as they do the product pipeline, writes Karin Van Baelen.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
